Learn peptides step by step

Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist

Amycretin puts GLP-1 and amylin in one molecule — with both a pill and a weekly shot in development. Here's the beginner map before Phase 3 ladders finalize.

Amycretin Dosing Guide: Oral Daily and Weekly Subcutaneous Protocols

Amycretin is Novo's dual GLP-1 + amylin molecule with both oral and injectable programs. Here's the early dosing map and why Phase 3 is the next SEO wave.

Amycretin vs CagriSema: One Dual Agonist vs Two-Drug Amylin Stack

Same company family of ideas — GLP-1 + amylin — two product architectures. Here's how amycretin compares to CagriSema without fake head-to-head rankings.

Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters

Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.

Eloralintide vs Cagrilintide: Amylin Agonists Compared

Both hit amylin biology. One is Lilly's Phase 3 monotherapy / combo candidate. The other is the amylin half of CagriSema. Here's a clear comparison for people following the next wave of obesity peptides.

Eloralintide Weight Loss Results: Phase 2 Data and What to Watch in Phase 3

Phase 2 put eloralintide on the board with roughly 9–20% mean weight loss at 48 weeks. Here's the results breakdown — and the troubleshooting mindset for plateaus on any amylin or GLP-1 protocol.

Survodutide Dosing Guide: Phase 2–3 Weekly Doses for Obesity

Survodutide is Boehringer's glucagon/GLP-1 dual agonist. Here's the dosing map from dose-finding through Phase 3 — weekly mg ranges, escalation logic, and what the weight-loss data showed.

Mazdutide Dosing Guide: 4 mg and 6 mg Weekly Protocols Explained

Mazdutide is a once-weekly glucagon/GLP-1 dual agonist with clear Phase 3 dose anchors at 4 mg and 6 mg. Here's the dosing and results map searchers want.

Orforglipron Dosing Guide: Oral GLP-1 Titration to 6, 12, and 36 mg

Orforglipron is Lilly's once-daily oral small-molecule GLP-1. Here's the titration ladder searchers want — 1 mg start, step-ups every four weeks, and Phase 3 maintenance doses.

Retatrutide's July 23 Phase 3 Readout Keeps Raising the Ceiling

Retatrutide just posted two more strong phase 3 wins. The new numbers matter, but the bigger story is how phase 1, phase 2, and phase 3 now line up into one very clear dose-response story.

Retatrutide Phase 3 Results: What They Mean for Appetite, Lean Mass, and Adherence

The real test for retatrutide is not whether it moves the scale. It is whether it makes the plan easier to follow without flattening training, energy, or lean mass.

Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data

The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.

Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide

The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.

Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means

31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.

Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard

New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.

Retatrutide Cuts Knee Pain by 75.8%: What the TRIUMPH-4 Trial Means Beyond Weight Loss

Everyone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.

Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard

Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.

Retatrutide TRIUMPH-4 Phase 3 Trial: 28.7% Body Weight Reduction Confirmed

Phase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.

Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows

TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.

Retatrutide Phase 3 Results: What the Clinical Data Tells Us

New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.